Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
May 16, 2024
Development cooperation has reached a crossroads. Humanitarian needs are rapidly increasing as violent conflicts erupt and continue, and geopolitical rivalry is contributing to a more fragmented development landscape. Difficult economic conditions in many of the poorest countries are paired with shr...
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
Blog Post
November 02, 2023
Geopolitical risks are rapidly converging, making the world more crisis-prone and precarious. Faced with a near economic collapse in some low and lower middle-income countries, the escalating devastation of climate-related disasters aggravating existing vulnerabilities, and a sharp rise in conflicts...
Blog Post
September 27, 2023
The rapid evolution of the development landscape, amid ongoing crises such as the war in Ukraine and climate change, presents profound challenges for all development actors. The various challenges intersect in unprecedented ways, amplifying the complexities faced by development cooperation providers...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...